Skip to main content
SpringerLink
Log in

What Can We Expect From Long-Acting Formulations for Schizophrenia?

  • CLINICAL TRIAL REPORT
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Division of Translational Neuroscience, Department of Psychiatry, University of Pennsylvania, Translational Research Laboratories, 125 South 31st Street, Philadelphia, PA, 19104, USA

    Steven J. Siegel

Authors
  1. Steven J. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven J. Siegel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siegel, S.J. What Can We Expect From Long-Acting Formulations for Schizophrenia?. Curr Psychiatry Rep 13, 243–244 (2011). https://doi.org/10.1007/s11920-011-0206-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-011-0206-2

Keywords

Search

Navigation